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When I was three years old my family was blessed with another child. I remember 
painting the room across the hall from mine a soft purple and putting glow-in-the-dark stars on 
the ceiling with my parents, anxiously awaiting the arrival of my baby sister. On February 16th of 
2000 she was born. It was quickly evident that something was very wrong. Many somethings. 
The National Organization for Rare Disorders (NORD) reported that in 2016 only 100 patients 
had been reported to have Pallister-Hall Syndrome. My sister was one of them. Pallister-Hall 
Syndrome disrupts the formation of organs and tissues during embryonic development (U.S. 
Library of National Medicine, Pallister-Hall Syndrome). As an incredibly rare disorder, very 
little is known about the origin and pathological properties. Judith Hall and Philip Pallister were 
the first to describe the condition in 1980 (NORD).  
The most common clinical symptoms of Pallister-Hall Syndrome (further on referred to 
as PHS) are polydactyly and syndactyly (distinguishable in Picture 1) - the presence of extra 
fingers or toes and the fusion of them through the bones – and a hypothalamic hamartoma 
(NORD).  It is important to note that the hypothalamic hamartoma is not a tumor but a 
malformation in the brain. This section of the brain grows with, or slightly slower, than the rate 
of surrounding tissue. It can be as large as four centimeters in the longest dimension. While these 
hamartomas may be large in size there is no correlation between its size and presence and 
severity of other symptoms (Biesecker). There are two types of polydactyly to look for in 
diagnosis. Postaxial polydactyly is the presence of an extra digit on the ulnar or fibular side of 
the hand and is more common. Mesoaxial, also known as central or insertional, polydactyly is 
the presence of a sixth digit formed off of the metacarpal or metatarsal bones. It is also important 
to note that in clinical diagnosis that there is a higher frequency of postaxial polydactyly in those 
of central African decent and that this should not be used as a key symptom (Biesecker).  
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Picture 1: Syndactyly and Polydactyly in patient with Pallister-Hall Syndrome 
As a pan ethic disorder (Biesecker), ethnicity cannot be used to determine risk in 
pregnancies and growing families. There are two ways to contract the syndrome. The first way is 
through hereditary information passed on from both parents. In this form PHS is expresses 
autosomal dominant characteristics, meaning that only one affected allele is needed for the 
mutation to be expressed, not two (Biesecker). If a patient were to be diagnosed with 
hereditarily-passed PHS, one of their parents would have also had to express the trait. The origin 
of PHS can be traced to the GLI3 gene. This gene is located at 7p14.1. (NIH, Pallister-Hall 
Syndrome). GLI3 provides instructions on how to create the GLI3 protein that regulates gene 
expression, by either inducing or repressing targeted genes. As a gene that controls whether or 
not certain pathways are turned on or off, it has a more than significant importance in shaping 
organs and tissues prior to birth (NIH, Pallister-Hall Syndrome).  
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Figure 1: Location of the GLI3 gene on the 7th chromosome from NIH, GLI3 gene 
It has been reported that the mutations responsible for PHS typically result in an 
abnormally short GLI3 protein. While the normal GLI3 protein can turn induce or repress certain 
genes, this short version can only repress (NIH, Pallister-Hall Syndrome). So far, this is the only 
gene known to cause PHS, but it is not a one to one ratio. Only 95% on patients with PHS have 
been identified to have the GLI3 mutation (NORD). The other type of inheritance of the 
syndrome is through a sporadic variant. One in four patients with PHS develop it through this 
new mutation and often express more severe and even lethal symptoms than those who inherit it 
through their parents (Biesecker). While only the handful of those who develop PHS experience 
the lethal phenotype, the possibility of death leads PHS to be placed in the ‘CAVE’ category of 
disorders- the cerebroacrovisceral early lethality group (Biesecker). As PHS symptoms vary 
drastically in affected patients it is very difficult to pinpoint the actual frequency of PHS in 
populations. As hypothalamic hamartomas can be asymptomatic and polydactyly is not all too 
rare, misdiagnoses are very likely on the mild end of the spectrum.  
The GLI3 protein produced is a bifunctional zinc finger transcription factor (GLI3 
mutations in syndromic…) that serves as both an activator and as a repressor (UniProtKB). 
When the protein are fully functional it aide in assembling the transcriptional activation 
complexes involved in targeting other genes. The GLI3 protein recognize 5’-GACCACCC-3’ in 
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their promoter regions. GLI3 protein has been determined to bind to a location on the PAF 
complex (known as CDC 73). These two work together to aide in RNA polymerase II-mediated 
transcription. Areas within the C-terminus have been shown to function with histone 
acetyltransferase CBP, TAF31, and Mediator component Med12 (GLI proteins bind 
promoters…). In one study (GLI3 mutations in syndromic…), certain nonsense mutations 
resulted in the loss of C-terminal domains, resulting in Postaxial Polydactyly and Greig-
Cephalopolysyndactyly syndrome. This results from the sudden lack of ability to function with 
histone acetyltransferase CBP, TAF31, and Mediator component Med12 (GLI proteins bind 
promoters…). It is mostly splicing and nonsense mutations of the middle third of the gene that 
tend to result in PHS (McKusick).  
Arguably the most important role of GLI3 proteins is their interaction with the Sonic 
Hedgehog Pathway (referred to as Shh). This pathway is essential in proper cell differentiation, 
proliferation, and tissue polarity. Some of the tissues specifically influenced are those of the 
lung, spleen, colon, placenta, uterus, and testes (UniProtKB). Many cancers have been linked 
back to the Shh pathway including lung, pancreas, prostate, breast, medulloblastoma, basal cell 
carcinoma, and malignant gliomas. This pathway is upstream of GLI zinc finger transcription 
factors. Various GLI proteins are turned on through Shh ligand mechanisms- both independent 
and dependent (Rimkus et al.). 
This is done through interaction of GLI3FL (full length form) and SUFU. The two form a 
neutral complex within the cytoplasm of the cell. This complex turns GLI3FL to GLI3 which 
then disassociates from SUFU, allowing it to move into the nucleus and repress Shh targeted 
genes. This only occurs in the absence of Shh signaling. When signals are present the two 
dissociate from each other and the targeted genes are not repressed. This halts creation of 
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GLI3R. The now available GLI3FL is moved into the nucleus where it is phosphorylated, 
destabilized, and turned into the transcriptional activator form (GLI3A) (UniProtKB). Various 
cells respond to Shh differently depending on the type of cell, time exposed, and the amount of 
exposure received. The latter two are determined by multiple feedback loops. Germline 
mutations (covered later) that work with Shh have been linked to various developmental 
disorders and somatic mutations have been linked to multiple forms of cancer (Varjosalo, M. & 
Taipale, J.).  
 Zinc finger transcription factors are proteins that regulate transcription and are composed 
of zinc fingers- the GLI3 protein is one of these. As stated earlier this protein can function as 
either as a repressor or an activator in its fully functioning form. One important lesson in 
biology, whether it be biochemistry or physiology, is that the shape of the protein dictates 
function. This is due to the chemical interactions between various molecules and the specificity 
required for two things to work together. Zinc fingers give GLI3 their shape. There are five 
located in the beginning of the second third of the 1580 amino acids (Figure 2). While there are 
five zinc finger locations there are only two binding areas, highlighted in dark teal. These 
binding sites are composed of two cysteines and two histidines. The different amount of finger 
areas to binding sites results in a complex shape, meaning a complex protein. An example of 
how one zinc finger forms around one Zn2+ ion is shown in Figure 3.  
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Figures 2 & 3: (2) 1,500 amino acid sequence with five zinc finger regions and two zinc finger 
binding domains highlighted. (3) 3rd zinc finger region and their binding with a Zn2+ through 
cysteines and histidines 
 While the National Institute of Health only published through Genetics Home Reference 
that an abnormally short GLI3 gene can result in PHS, OMIM confirms on “Oncogene GLI3” 
that the truncation more often than not occurs in the middle third of the gene- where zinc finger 
binding occurs. OMIM also reports that patients with mutations in the first third and last third of 
the gene were patients with Greig Cephalopolysyndactyly Syndrome. Not only does this support 
the hypothesis that Greig Cephalopolysyndactyly Syndrome and PHS have identifiably different 
pathologies, but also suggests that the five zinger fingers are what are most vital in the process of 
normal activation and repression. Shape dictates function, and in this case it becomes readily 
apparent that varying the folding pattern prevents targeted genes from recognizing and reacting 
to the protein.  
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It is an incorrect assumption that PHS is strictly a severe condition and that Greig 
Cephalopolysyndactyly syndrome is a mild one. This disorder, which also affects the GLI3 gene, 
is sometimes confused with PHS due to their “mild” similarities. The assumption is inaccurate as 
not all individuals affected by PHS display severe and lethal symptoms- most cases are mild 
(Biesecker). This can lead patients with PHS to be misdiagnosed as having Greig 
Cephalopolysyndactyly. Mild PHS is also commonly misdiagnosed as isolated postaxial 
polydactyly type A. PHS can also cause severe pituitary insufficiency through the hypothalamic 
hamartoma, causing possible patients to die as neonates, resulting in a miscarriage (Biesecker). 
PHS can still be misdiagnosed as Ellis Van Creveld syndrome, craniopharyngioma, Bardet-Biedl 
syndrome, oral-face-digital syndrome type 6, Holzgreve-Wagner Rehder syndrome, Smith-
Lemli-Opitz dynrome, and congenital hypothalamic harmartoma syndrome (Orpha).  
 
Picture 2: Pallister-Hall Syndrome is in the ‘CAVE’ category of disorders- the 
cerebroacrovisceral early lethality group 
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Neonates are typically miscarried due to the body’s ‘knowledge’ that something has gone 
awry but sometimes pregnancies with fatal complications are brought to term. The two 
complications thought to be directly linked to early fatality are pan hypopituitarism caused by 
hypothalamic or pituitary dysplasia and laryngotracheal cleft, particularly posterior clefts 
(Biesecker). Bifid epiglottis tends to be asymptomatic. This anterior-posterior midline cleft 
within the epiglottis is incredibly useful in clinical diagnoses as it is very rare as an isolated 
malformation (Biesecker). Past infancy PHS is treatable, but not curable. Endocrine 
abnormalities rise as a result of the hypothalamic hamartoma. The two main manifestations, 
aside from the fatal pan hypopituitarism, are isolated growth hormone deficiency and isolated 
precocious puberty. It has been recorded that de novo forms of PHS can also spur cortisol 
deficiency, which seems to be uncommon in patients with familial PHS (Biesecker).  
For those who have symptomatic hypothalamic hamartomas, gelastic epilepsy is expected 
to be a complication. This neurological partial seizure manifests itself as repetitive spasms of 
diaphragm and chest, mimicking laughter (Biesecker). This problem is often not discovered until 
patients are old enough to convey that something is wrong. The remainder of observed 
symptoms in literature may not all be tied to PHS, but are common in some patients. Some mild 
observations include upturned nostrils, a flat bridge of the nose, and a visible vertical groove in 
the patient’s upper lip (midline) (NORD). Low-set posteriorly rotated ears have also been 
common (OrphaNet). These facial symptoms can be seen in Picture 3. Natal teeth, buccal frenula 
(movement-reducing mucous membrane tissue in the mouth), short limbs, dislocated hips, 
agenesis or dysplasia of kidneys, and congenital heart defects have all been observed in patients 
as well (NORD). With the wide range and severity of possible symptoms it is assumed that 
possible patients are OK until proven otherwise (OrphaNet).  
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Picture 3: Upturned nostrils, flat bridge of nose, vertical groove in upper lip, and low-set 
posteriorly rotated ears in patient with Pallister-Hall Syndrome 
For those plagued with PHS in its non-fatal form life goes on. There are many steps taken 
to ensure PHS stays in check throughout the remainder of development and adolescence. The 
most common symptom, polydactyly, is often fixed quickly during infancy by removing the 
extra digit surgically (NORD). Hormonal replacement therapy is the best course of action for 
those who experience hypopituitarism. This type of therapy typically relieves all symptoms 
(NORD). Those who experience gelastic seizures as a result of the hypothalamic hamartoma can 
take anticonvulsant medication to reduce the effects (NORD). As the hamartoma is a 
malformation and not a tumor, it is not suggested to remove it. Removing the malformation is 
expected to result in furthered pituitary insufficiency (Biesecker). As patients grow it is 
important to have yearly developmental assessments and evaluations to keep an eye out for 
precocious puberty (Biesecker). Perhaps the most difficult part of living with PHS is the toll it 
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takes on patients and their families. Those who are affected and their families are encouraged to 
meet with a Genetics Counselor (NORD).  
Determining whether one has PHS can be done two ways- clinically and through genetic 
testing. Many clinical tests can be done, including a brain MRI, X-rays of both hands and feet, a 
renal ultrasound, and a laryngoscopy (OrphaNet). As polydactyly and the hamartoma are the 
most common symptoms the basic clinical diagnosis requires the presence of both (Biesecker). 
The hypothalamic hamartoma is shown in MRIs as a midline mass isointense to surrounding 
gray matter (OrphaNet). If both landmark symptoms are present genetic testing is completed. 
Single-gene testing is comprised of both analysis of the GLI3 gene and duplication analysis, 
though duplication is rare in PHS. Some laboratories may sequence just the exons (expressed 
regions of the gene) to begin testing. The exons examined are between codons 667 and 1161. 
Multi-gene testing may be completed instead to test other genes that may be responsible, if other 
diagnoses may be possible. If these genetic tests come back inconclusive, more genetic testing is 
available, including whole-exome sequencing, whole mitochondrial sequencing, and whole-
genome sequencing (Biesecker).   
After my sister was born with Pallister-Hall Syndrome both of my parents were clinically 
tested for syndactyly and the hypothalamic hamartoma. Both tests came back negative. In 2000, 
much less was known than is today, and it was concluded that my mother had come into contact 
with something during a fragile stage in her pregnancy. In personal communication with Julie 
Sapp, a researcher at NIH, in December, it was determined that that conclusion is inaccurate. If 
that were the case, there would be many more occurrences of Pallister-Hall Syndrome. It is most 
likely that my sister experienced a de novo variant. Her symptoms were so severe that doctors 
were astounded she came to term, which reflects well with the literature on de novo variants. The 
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lack of certainty in just how rare the disease is due to misdiagnoses, miscarriages, common 
postaxial polydactyly, and asymptomatic hypothalamic hamartomas, creates a lot of questions in 
affected families. In speaking with Sapp, while not likely at all, it is theoretically possible that 
Pallister-Hall Syndrome runs in my family (refer to Figure 2 and 3). The one other explanation is 
that of germline mosaicism. There has been only one case that mosaicism was identified in 
(Sapp), but it is possible. Germline mosaicism is a phenomenon in which a mutation occurs 
either in a germ cell or in a somatic cell prior to division into germinal cells (Zlotogora). In this 
event, the affected parent either expresses no symptoms at all (if the mutation is just in germinal 
cells) or very few, if at all, symptoms (if in early in a somatic cell) but the affected offspring 
displays all symptoms. Despite the clinical tests coming back negative 17 years ago, Sapp has 
suggested genetic testing for my parents for more definite and conclusive answers. While much 
has been learned over the past two decades about Pallister-Hall Syndrome, there is still so much 
more to learn. 
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Figure 2: Pedigree of likely de novo inheritance of Pallister-Hall Syndrome 
 
Figure 3: Pedigree of possible autosomal dominant inheritance of Pallister-Hall Syndrome 
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